Ribonucleotide reductase as a therapeutic target for drug repurposing as anthelmintics

被引:2
|
作者
Panesso, Marcelo Pasa [1 ,2 ,3 ]
Cancela, Martin
Cora, Renato Kulakowski [1 ,2 ,3 ]
Paes, Jessica Andrade [1 ,2 ,3 ]
Paludo, Gabriela Prado [1 ,2 ,3 ]
Ferreira, Henrique Bunselmeyer [1 ,2 ,4 ]
机构
[1] Univ Fed Rio Grande do Sul UFRGS, Ctr Biotecnol, Lab Genom Estrutural & Func, Porto Alegre, Brazil
[2] Ctr Biotecnol, Lab Biol Mol Cestodeos, UFRGS, Porto Alegre, Brazil
[3] Univ Fed Rio Grande do Sul, Ctr Biotecnol, Programa Posgrad Biol Celular & Mol, Porto Alegre, Brazil
[4] Univ Fed Rio Grande do Sul, Inst Biociencias, Dept Biol Mol & Biotecnol, Porto Alegre, Brazil
关键词
Nucleotide synthesis; Echinococcus granulosus; Helminthiasis; Druggability; Drug repurposing; IN-VITRO; ECHINOCOCCUS; HYDROXYUREA; METABOLISM;
D O I
10.1016/j.exppara.2023.108641
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Visceral cestodiases, like echinococcoses and cysticercoses, are zoonoses of worldwide distribution and are responsible for public health problems in many countries, especially in underdeveloped regions. Current treatments have low efficiency and there are few drugs currently in use for chemotherapy, making the development of new anthelmintics an urgent matter. The nucleotide salvage pathways are the only ones available for nucleotide synthesis in cestodes and other parasitic helminths, and, here, we used in silico approaches to assess the potential of the enzymes in these pathways as targets for drug repurposing as anthelminthics. First, a genomic survey allowed to identify a repertoire of 28 enzymes of the purine and pyrimidine salvage pathways from the cestode Echinococcus granulosus sensu stricto. Regarding purines, the parasite relies on salvaging free bases rather than salvaging nucleosides. Pyrimidines, on the other hand, can be salvaged from both bases and nucleosides. Druggability of the parasite enzymes was assessed, as well as the availability of commercial inhibitors for them. Druggable enzymes were then ranked according to their potential for drug repurposing and the 17 most promising enzymes were selected for evolutionary analyses. The constructed phylogenetic trees allowed to assess the degree of conservation among ortholog enzymes from parasitic helminths and their mammalian hosts. Positive selection is absent in all assessed flatworm enzymes. A potential target enzyme for drug repurposing, ribonucleotide reductase (RNR), was selected for further assessment. RNR 3D-modelling showed structural similarities between the E. granulosus and the human orthologs suggesting that inhibitors of the human RNR should be effective against the E. granulosus enzyme. In line with that, E. granulosus protoscolices treated in vitro with the inhibitor hydroxyurea had their viability and DNA synthesis reduced. These results are consistent with nucleotide synthesis inhibition and confirm the potential of a nucleotide salvage inhibitors for repurposing as an anthelmintic.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] INTERACTION OF RIBONUCLEOTIDE REDUCTASE WITH RIBONUCLEOTIDE ANALOGS
    FOLLMANN, H
    HOGENKAMP, HP
    BIOCHEMISTRY, 1971, 10 (01) : 186 - +
  • [32] Ribonucleotide reductase subunit switching in hepatoblastoma drug response and relapse
    Anthony Brown
    Qingfei Pan
    Li Fan
    Emilie Indersie
    Cheng Tian
    Nikolai Timchenko
    Liyuan Li
    Baranda S. Hansen
    Haiyan Tan
    Meifen Lu
    Junmin Peng
    Shondra M. Pruett-Miller
    Jiyang Yu
    Stefano Cairo
    Liqin Zhu
    Communications Biology, 6
  • [33] Ribonucleotide reductase subunit switching in hepatoblastoma drug response and relapse
    Brown, Anthony
    Pan, Qingfei
    Fan, Li
    Indersie, Emilie
    Tian, Cheng
    Timchenko, Nikolai
    Li, Liyuan
    Hansen, Baranda S. S.
    Tan, Haiyan
    Lu, Meifen
    Peng, Junmin
    Pruett-Miller, Shondra M. M.
    Yu, Jiyang
    Cairo, Stefano
    Zhu, Liqin
    COMMUNICATIONS BIOLOGY, 2023, 6 (01)
  • [34] Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma
    Sagawa, Morihiko
    Ohguchi, Hiroto
    Harada, Takeshi
    Samur, Mehmet K.
    Tai, Yu-Tzu
    Munshi, Nikhil C.
    Kizaki, Masahiro
    Hideshima, Teru
    Anderson, Kenneth C.
    CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5225 - 5237
  • [35] Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase
    Hashemy, SI
    Ungerstedt, JS
    Avval, FZ
    Holmgren, A
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (16) : 10691 - 10697
  • [36] Overcoming cancer therapeutic bottleneck by drug repurposing
    Zhe Zhang
    Li Zhou
    Na Xie
    Edouard C. Nice
    Tao Zhang
    Yongping Cui
    Canhua Huang
    Signal Transduction and Targeted Therapy, 5
  • [37] Overcoming cancer therapeutic bottleneck by drug repurposing
    Zhang, Zhe
    Zhou, Li
    Xie, Na
    Nice, Edouard C.
    Zhang, Tao
    Cui, Yongping
    Huang, Canhua
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
  • [38] The enzyme ribonucleotide reductase: Target for antitumor and anti-HIV therapy
    Szekeres, T
    Fritzer-Szekeres, M
    Elford, HL
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 1997, 34 (06) : 503 - 528
  • [39] Ribonucleotide reductase M2 subunit as novel target for liposarcoma
    Geha, Rula C.
    Wu, Vicotria
    DeCarolis, Penelope
    O'Connor, Rachael
    Chen, JinHong
    Schwartz, Gary
    Singer, Samuel
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2006, 203 (03) : S86 - S86
  • [40] Ribonucleotide reductase enzyme a target for titanium complexes: A strategy to cure cancer
    Gaur, Kavita
    Perez, Sofia
    Akam, Eman
    Tomat, Elisa
    Saxena, Manoj
    Sharma, Rohit
    Tinoco, Arthur
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 253